Travere Therapeutics (TVTX) Guggenheim’s Inaugural Healthcare Innovation Conference summary

Key product and clinical program updates

• Achieved full approval for FILSPARI in IgA nephropathy, driving strong commercial uptake and positive sales momentum in Q3, with over 500 new patient starts despite seasonal slowdowns.

• Advancing FSGS program with sparsentan, leveraging new PARASOL consortium findings that support proteinuria-based endpoints for regulatory approval; Type C FDA meeting scheduled, with an update expected by the next earnings call.

• Pegtibatinase program for classical homocystinuria paused phase III enrollment due to manufacturing scale-up needs, with plans to resume enrollment in 2026.

• Filed sNDA to reduce liver monitoring for FILSPARI from monthly to quarterly, aiming to improve patient convenience and align with standard lab schedules.

• Ex-U.S. launches progressing in Europe and Japan through partnerships, with early-stage launches in Germany, Austria, and Switzerland.

Regulatory and industry landscape

• PARASOL consortium's analysis of 1,600 FSGS patients across 30 databases led to consensus that proteinuria, not eGFR, should be the primary regulatory endpoint, aligning with internal clinical data.

• FSGS remains a high unmet need with no approved treatments and a smaller but urgent patient population compared to IgAN.

• Draft kidney guidelines now recommend earlier and more ambitious treatment for IgAN, lowering proteinuria thresholds and supporting combination therapy, which positions FILSPARI as foundational care.

• EMA was less involved than FDA in PARASOL but remains engaged; regulatory strategy in Europe will be coordinated with CSL Vifor.

Financial and operational outlook

• Cash position of $277 million as of Q3, providing runway into 2028; recent financing adds flexibility for FSGS-related investments.

• Key catalysts over the next 12–18 months include quarterly commercial updates, FSGS regulatory milestones, sNDA progress, and updates on pegtibatinase manufacturing and European launches.